Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers

• Material Type: 博士論文
• Title: Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers
• Author/Editor: Tono, Yasutaka
• Author Heading: Tono, Yasutaka
• Publication, Distribution, etc.: 三重大学
• Publication Date: 2018-03-26
• Publication Date (W3CDTF): 2018-03-26
• Alternative Title: 既治療進行HER2陽性乳癌に対するペルツズマブ・トラスツズマブ・エリブリン療法：バイオマーカー解析を加えたfeasibility study
• Degree grantor/type: 三重大学
• Date Granted: 2018-03-26
• Date Granted (W3CDTF): 2018-03-26
• Dissertation Number: 甲医学第1880号
• Degree Type: 博士(医学)
• Conferring No. (Dissertation): 甲医学第1880号
• Text Language Code: eng
• Alias of Author: トノ, ヤスタカ; 戸野, 泰孝
• Subject Heading: HER2-positive; breast cancer; eribulin mesylate; pertuzumab; trastuzumab
• Target Audience: 一般
• Note (General): application/pdf; The standard treatment for advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is the triple combination of pertuzumab, trastuzumab and docetaxel, but some patients cannot tolerate taxane. To explore a non-taxane triple therapy, we conducted a feasibility study of pertuzumab, trastuzumab and eribulin mesylate (PTE) therapy for previously treated advanced HER2-positive breast cancer with analyses of quality of life and biomarkers. Ten patients were enrolled, two of whom had a history of docetaxel allergy. The median number of prior regimens was 3. The most common Grade 3 toxicities were leukopenia (70%) and neutropenia (70%). Grade 4 or 5 adverse events were not observed. An improving trend for the Functional Assessment of Cancer Therapy-Breast (FACT-B) score at 3 months was observed. Eight cases were included in the biomarker analysis. The peripheral CD8+ T cell/ CD4+Foxp3+ regulatory T cells (Tregs) ratio was significantly increased (p = 0.039). The frequency of peripheral Tregs was associated with the trastuzumab trough concentration (p = 0.019). In a non-clinical analysis, Eribulin mesylate significantly inhibited Ser473 Akt phosphorylation in PIK3CA wild-type cells and mutated cells. These results suggest that PTE therapy is a feasible and promising option for advanced HER2-positive breast cancer. Further investigation is warranted.; 本文 / Department of Hematology and Oncology, Mie University Graduate School of Medicine; 47p
• DOI: info:doi/10.18632/oncotarget.24504; https://doi.org/info:doi/10.18632/oncotarget.24504
• Persistent ID (NDL): info:ndljp/pid/11123704; https://dl.ndl.go.jp/pid/11123704
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2018-08-03T23:36:01+09:00
• Date Created (W3CDTF): 2018-07-18
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10076/00017687; https://mie-u.repo.nii.ac.jp/records/12054
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2023-12-15 再収集